BRAF and colorectal cancer: A Randomized Trial of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or FOLFIRI/Cetuximab in Chinese Patients With BRAF&lt;sup&gt;V600E&lt;/sup&gt; Mutant Metastatic Colorectal Cancer: The NAUTICAL Study.